Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076755 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10L3MBTL1FFAR4KDM4E | |
| SCHEMBL6447970 | 0.92 | ALDH1A1 (0.34) | ALDH1A1HSD17B10FFAR4DAO | |
| SCHEMBL6078326 | 0.92 | ALDH1A1 (0.34) | ALDH1A1HSD17B10FFAR4DAO | |
| SCHEMBL6077017 | 0.92 | RIPK1 (0.36) | ALDH1A1HSD17B10L3MBTL1KDM4EMITF | |
| SCHEMBL6870225 | 0.92 | RIPK1 (0.36) | ALDH1A1HSD17B10L3MBTL1KDM4EMITF | |
| SCHEMBL6077279 | 0.87 | RPA1 (0.33) | ALDH1A1HSD17B10 | |
| SCHEMBL6077756 | 0.87 | CYP1A2 (0.36) | ALDH1A1HSD17B10KDM4E | |
| SCHEMBL6077936 | 0.87 | CYP1A2 (0.36) | ALDH1A1HSD17B10KDM4E | |
| SCHEMBL6076895 | 0.87 | RPA1 (0.33) | ALDH1A1HSD17B10 | |
| SCHEMBL6077514 | 0.86 | ALDH1A1 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890942-B2 | Acyl sulfonamides as inhibitors of HIV integrase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20050004232-A1 | Acyl sulfonamides as inhibitors of HIV integrase | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-06 | — | — | US | disclosed |
| WO-2004103278-A2 | ACYL SULFONAMIDES AS INHIBITORS OF HIV INTEGRASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-02 | — | — | WO | disclosed |
| EP-1467695-A2 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
| WO-2003049690-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004232-A1 | Acyl sulfonamides as inhibitors of HIV integrase | ACSS2, ARSA, ASS1 | ALDH1A1 640/4885HSD17B10 167/4885L3MBTL1 790/4885 |
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | ALDH1A1 976/4885HSD17B10 718/4885L3MBTL1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.